For adults with treatment-resistant depression, adding mindfulness-based cognitive therapy (MBCT) to usual pharmacotherapy produced a significantly greater reduction in depression severity (36.6% vs. 25.3% on the Hamilton Depression Rating Scale) and a higher rate of treatment responders (30.3% vs. 15.3%) after eight weeks, compared with an active control program of physical fitness, music therapy, and nutritional education. Remission rates did not differ significantly between groups (22.4% vs. 13.9%). Higher state anxiety, perceived stress, and personality disorder were associated with worse outcomes. MBCT appears to be a viable adjunctive treatment for treatment-resistant depression.
A panel of experts from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners used a Delphi process to develop consensus guidelines for administering intravenous ketamine infusions to treat depressive disorders. The guidelines provide recommendations on patient selection, dosing, safety monitoring, and treatment protocols, aiming to standardize clinical practice and improve patient outcomes. The consensus reflects agreement among specialists on best practices for this off-label use of ketamine.
Under Oregon's regulated psilocybin program, adults who consumed an average of 27.8 mg of psilocybin showed significant improvements in depression, anxiety, and well-being 30 days after a session, including those concurrently using psychiatric medication. Of 88 participants (median age 43, 52% male, 64.8% with prior psychedelic experience), two reported symptoms of hallucinogen persisting perception disorder one day after the session, but none at 30 days. The findings suggest that legal psilocybin services can produce clinically meaningful mental health benefits.